PFIZER-ALLERGAN – THE RISE AND FALL OF A MEGA-MERGER Case Solution
The deal cost of USD363.63 per Allergan share equates into a 27% pemium for Allergan investors and an overall business worth for Allergan of about USD160 billion. Regardless of the reality that the offer has the possible to alter the affordable landscape of the general market, monetary experts discuss the unfavorable stock-market action with the offer being ill-timed. Therefore, Pfizer prepared a so-called inversion offer intending at the moving of head office to foreign tax programs in order to decrease the efficient business tax rate
This is just an excerpt. This case is about Business
Related Case Solutions & Analyses:
Donna Klein and Marriott International Inc. (B)
Case of the Colored Post-It Notes
Southland Corp. (B)
Cat Fight in the Pet Food Industry (A)
Sleepmore Mattress Manufacturing: Plant Consolidation
Interview with Anders Byriel and Mads Nygard: Kvadrat, Video
General Electric’s Expansion in the Middle East
WebTracker
Angel Investments in Europe and Recent Developments in Crowdfunding
Zomeworks Corporation: Design Driven Innovation
